AVBPArriVent BioPharma, Inc.Running, no new patients
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
Metastatic Non-Small Cell Lung Cancer · Advanced Non-Small Cell Lung Cancer · EGFR Exon 20 Mutations
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 398 (final count)
- Started
- Jun 1, 2023
- Main results expected
- Oct 6, 2026
- Fully finished
- Feb 15, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS) determined by blinded independent central review (BICR)
Measured over: Up to 32 months after first dose
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05607550 · record last updated 2026-11-02 · checked 2026-11-09 15:47 UTC